Company intelligence / Profile preview

DIOSynVax

Cambridge, England, United Kingdomdiosynvax.com ↗

Ownership: Private
Development stage: Phase 1

Overview

DIOSynVax has demonstrated safety in a "First-in-Human" Phase I trial of its digitally engineered coronavirus vaccine. Its bird flu/universal influenza candidate has shown efficacy and safety in animal models and is ready to enter human trials. The company’s approach leverages AI-driven computational biology to design broad-spectrum synthetic antigens that elicit robust immune responses against highly variable pathogens.

Therapeutic areas: Infectious Diseases
Modalities: Synthetic vaccine antigens (digitally engineered)mRNA (in partnership programs)Multivalent vaccine antigen payloads (VAPs)
Industry: Biotech

Drug pipeline

6 assets

DIOSynVax Bird Flu vaccine

Preclinical

5 more assets in the full pipeline.

Request access →

Partnerships

ProBioGen AG (manufacturing partner for hemorrhagic fever vaccine candidate)Ethris GmbH (mRNA delivery technology collaboration)University of Cambridge spinout/collaboration origin

Beyond the preview

Go deeper on DIOSynVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DIOSynVax.

Explore the full profile